Matt shares overall responsibilities for all management and investment activities of the firm. Matt has primary responsibility for Arlington’s healthcare investments and shares responsibility for the firm’s aerospace and defense investments. Matt has closed leveraged buyouts, recapitalizations and growth equity investments representing approximately $3.0 billion in value during his 20 year career in private equity. Matt’s private equity experience encompasses a wide range of industries including healthcare services, aerospace, defense, industrial manufacturing, specialty distribution and media. Prior to joining Arlington in 2001, Matt worked at Stonington Partners, a $1.0 billion private equity fund established in 1994 by the principals of Merrill Lynch Capital Partners. At Stonington, Matt worked on several healthcare transactions including Packard BioScience Corporation and Obagi Medical Products. Both companies ultimately completed initial public offerings before successful sale transactions. Matt’s responsibilities at Stonington included originating and conducting due diligence of investment opportunities, structuring and negotiating transactions, arranging public and private debt financing, designing management incentive plans and participating in portfolio company management and realizations. Matt was also directly involved in the monitoring and realization of Merrill Lynch Capital Partners investments.
Matt earned an M.B.A. from the Stanford Graduate School of Business. Matt graduated summa cum laude from Duke University with a B.A. in Economics.
Matt currently serves on the Board of Directors of Endeavor Robotics, Grand River Aseptic Manufacturing, Molecular Products, Ontario Systems, Tex Tech Industries and United Flexible. Matt has previously been a member of the Board of Directors of Advanced Health Media, Avalign Technologies, Cambridge Major Laboratories, Chandler/May, Cherry Creek Radio, Consolidated Precision Products, Main Line, MB Aerospace, Micron Technologies and New Vision Group.